Theravance Biopharma Inc (TBPH NASDAQ) stock market data APIs
$14.1403
-0.22(-1.6%)
as of September 17, 2025
Try our APIs with
free plan!
Theravance Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Prev. Close
14.1403
Open
13.9171
High
14.1393
Low
14.0331
52 wk Range
7.88-14.55
Market Cap
708 M
P/E Ratio
58.5417
Shares Outstanding
50 361 K
Revenue
77 205 K
EPS
-0.0842
Beta
0.047
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Theravance Biopharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Theravance Biopharma Inc data using free add-ons & libraries
Get Theravance Biopharma Inc Fundamental Data
Theravance Biopharma Inc Fundamental data includes:
- Net Revenue: 77 205 K
- EBITDA: -33 961 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-04
- EPS/Forecast: 0.6731
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Theravance Biopharma Inc News
New
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Theravance Biopharma (TBPH). Shares have added about 9.8% in that time frame, outperforming the S&P 500. But investors have to be wondering, wil...
Theravance Biopharma stock rating reiterated at Buy by BTIG
Investing.com - Theravance Biopharma (NASDAQ:TBPH) received a reiterated Buy rating from BTIG, which maintained its $25.00 price target on the stock. The target represents significant upside potential...
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Theravance Biopharma TBPH reported second-quarter 2025 adjusted net loss of 8 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 14 cents. In the year-ago quarter, the ...
Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout
Earnings Call Insights: Theravance Biopharma, Inc. (TBPH) Q2 2025 MANAGEMENT VIEW * CEO Rick E. Winningham highlighted "an excellent quarter, underscored by disciplined execution across our commer...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
